<DOC>
	<DOCNO>NCT02872116</DOCNO>
	<brief_summary>The main purpose study compare long patient gastric gastroesophageal junction cancer live receive nivolumab ipilimumab nivolumab chemotherapy compare patient receive chemotherapy alone .</brief_summary>
	<brief_title>Efficacy Study Nivolumab Plus Ipilimumab Nivolumab Plus Chemotherapy Against Chemotherapy Stomach Cancer Stomach/Esophagus Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Male Female least 18 year age Must gastric cancer gastroesophageal junction cancer operate advanced spread Did receive neoadjuvant adjuvant treatment ( chemotherapy , radiotherapy , ) disease within last 6 month Must full activity , limited , must able walk carry light activity light house work office work Must agree provide tumor tissue sample , either previous surgery biopsy within 6 month fresh , prior start treatment study Presence tumor cell brain spinal cord treat Active know suspect autoimmune disease Any serious uncontrolled medical disorder active infection Known history positive test human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Any positive test result hepatitis B C indicate acute chronic infection Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>